Nord and Nordic: On average, Wegovy tablets show significantly better weight loss effects than orforglipron.

On April 3, Novo Nordisk announced that they will present the results of the ORION study at the Obesity Medicine Association annual meeting in San Diego. The ORION study is a population-adjusted indirect treatment comparison that evaluates the weight loss efficacy and tolerability of semaglutide 25 mg tablets compared to Eli Lilly's orfor gliptin 36 mg based on data from phase 3 OASIS 4 and ATTAIN-1 clinical trials. The study showed significantly greater average weight loss with Wegovy tablets 25 mg compared to orfor gliptin 36 mg in a population-adjusted indirect treatment comparison.